Nicholas A. Butowski, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Nicholas A. Butowski, MD

Assistant Professor, Department of Neurological Surgery, and Director, Neuro-Oncology Clinical Services, UCSF

Phone: (415) 353-7500 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

My research includes a wide range of clinical trials, including those with convection enhanced delivery (CED) with real-time MR imaging, targeted agents, and immunotherapy. I am also active in translational research via the UCSF Brain Tumor Research Center Preclinical Core. As PI or co-Investigator on university-, industry-, and NIH-funded grants, I helped create the groundwork for allied research and a clinical trial portfolio at UCSF for patients with primary brain and spine tumors including an assortment immunotherapy trials (e.g., Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma [ACT IV]). I have also designed investigator initiated trials, including a clinical trial employing intratumoral delivery with real-time MRI imaging (Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium In Patients With Recurrent High Grade Glioma; 5R21CA186140-02). I have also authored a number of other clinical trials that will utilize novel theraputics and delivery systems.

Education

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Intern, 1999-2000, Medicine
University of California, San Francisco, San Francisco, CA, Fellow, 2003-2005, Neuro-Oncology


Professional Experience

  • 2000-2003
    Residency in Neurology; Department of Neurology, University of California, San Francisco, CA
  • 2003-2004
    Fellow, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
  • 2004-2005
    Clinical Instructor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
  • 2005-present
    Assistant Clinical Professor, University of California, San Francisco, Department of Neurological Surgery, Neuro-Oncology Service
  • 2006-present
    Director of Clinical Services, Dept. of Neurological Surgery, Neuro-Oncology Service, Brain Tumor Research Center, University of California, San Francisco (UCSF)
  • 2005-present
    Assoc Member of the Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF
  • 2005-present
    Assoc Member of the Comprehensive Cancer Center, UCSF
  • 2009-present
    Co-chair, CNS Cancer Program Site Committee
  • 2009-present
    Member, UCSF Cancer Program Protocol Review Committee
  • 2009-present
    Member, National Comprehensive Cancer Center Network CNS Cancer Guideline Committee

Selected Publications

  1. In Reply: Survival With Glioblastoma Multiforme and the Timing of Chemoradiation. Neurosurgery. 2016 Feb; 78(2):E315.
    View on PubMed
  2. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec; 8(6):446-55.
    View on PubMed
  3. Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202.
    View on PubMed
  4. Neurocognitive Function in Newly Diagnosed Low-grade Glioma Patients Undergoing Surgical Resection With Awake Mapping Techniques. Neurosurgery. 2015 Sep; 77(3):371-9.
    View on PubMed
  5. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53.
    View on PubMed
  6. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  7. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma†. Neuro Oncol. 2016 Jan; 18(1):87-95.
    View on PubMed
  8. Epidemiology and diagnosis of brain tumors. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):301-13.
    View on PubMed
  9. Central nervous system cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23.
    View on PubMed
  10. NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification. Mol Cancer Ther. 2014 Dec; 13(12):2919-29.
    View on PubMed
  11. Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014 Oct; 41 Suppl 6:S4-S13.
    View on PubMed
  12. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40.
    View on PubMed
  13. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90.
    View on PubMed
  14. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62.
    View on PubMed
  15. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014 Jun; 41 Suppl 4:S1-14.
    View on PubMed
  16. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9.
    View on PubMed
  17. A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields. Semin Oncol. 2013 Dec; 40(6):S2-4.
    View on PubMed
  18. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 1; 11(9):1114-51.
    View on PubMed
  19. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg. 2013 Sep; 115(9):1795-801.
    View on PubMed
  20. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013 Apr; 15(4):480-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI